RE:Taurx ValueI would agree that the Biogen approval paves the way for other dimentia drug approvals.
In terms of valuation, Dundee is carrying its investment in Taurx at CA$70M (or $55 per Taurx share). About a year ago Taurx raised $100M at $200 per share. This most recent raise was a different class of Taurx shares than what Dundee owns.... this new class of Taurx shares is convertible on a 1 for 1 basis into Taurx' common stock (that Dundee owns) but includes a call option to purchase commercialization rights in certain Asian regions.
My guess is that IF Taurx gets approval Dundee's investment in Taurx could be worth many times its current market cap (Biogen's market value increased by $20B with its approval the other month)... This is of course a big "IF".
Taurx could also be an interesting acquisition opportunity for a larger drug company trying to get exposure to Alzheimer's treatments.